Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,089 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01613950 | PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01928459 | Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 9, 2020 | clinicaltrials |
| NCT03619239 |
| Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma(GBM) |
| completed |
| Phase 1 |
| 15 |
| Genexine, Inc.INDUSTRY |
| 1 |
| Nov 10, 2020 |
| clinicaltrials |
| NCT04262739 | MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Haim Bio Co., Ltd.INDUSTRY | 1 | Oct 20, 2020 | clinicaltrials |
| NCT03272256 | Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma | completed | Phase 1 | 22 | ImmunoMet Therapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01948297 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | terminated | Phase 1 | 77 | Debiopharm International SAINDUSTRY | 5 | Sep 9, 2020 | clinicaltrials |
| NCT03276988 | Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients | completed | Phase 1 / Phase 2 | 8 | Genexine, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT04510415 | Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI | terminated | Phase 1 | 2 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01403948 | BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 3 | Aug 11, 2020 | clinicaltrials |
| NCT02405065 | Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 | completed | Phase 1 | 72 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT03118817 | Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers | completed | Phase 1 | 65 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT03778619 | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin | unknown | Phase 1 / Phase 2 | 9 | GC Cell CorporationINDUSTRY | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01199055 | CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 16 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02812875 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | completed | Phase 1 | 71 | Curis, Inc.INDUSTRY | 4 | Jun 26, 2020 | clinicaltrials |
| NCT01742286 | Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) | completed | Phase 1 | 83 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 9, 2020 | clinicaltrials |
| NCT03644056 | Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors | completed | Phase 1 | 15 | ImmuneOncia Therapeutics Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02624986 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | terminated | Phase 1 / Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 5 | May 18, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT03733587 | GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors | completed | Phase 1 | 24 | Genexine, Inc.INDUSTRY | 1 | May 14, 2020 | clinicaltrials |
| NCT03478995 | Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | Genexine, Inc.INDUSTRY | 1 | May 11, 2020 | clinicaltrials |
| NCT02013219 | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 6 | Apr 21, 2020 | clinicaltrials |
| NCT03002376 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) | completed | Phase 1 | 47 | Regeneron PharmaceuticalsINDUSTRY | 4 | Apr 20, 2020 | clinicaltrials |
| NCT03198130 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) | completed | Phase 1 | 33 | Regeneron PharmaceuticalsINDUSTRY | 2 | Mar 19, 2020 | clinicaltrials |
| NCT03558607 | The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm | unknown | Phase 1 / Phase 2 | 17 | Seoul National University HospitalOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | completed | Phase 1 | 196 | GlaxoSmithKlineINDUSTRY | 7 | Mar 16, 2020 | clinicaltrials |
| NCT02058381 | A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer(B-YOND) | completed | Phase 1 | 40 | Novartis PharmaceuticalsINDUSTRY | 4 | Mar 9, 2020 | clinicaltrials |
| NCT02401542 | Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-21) | terminated | Phase 1 / Phase 2 | 71 | Rainier TherapeuticsINDUSTRY | 9 | Mar 9, 2020 | clinicaltrials |
| NCT02261220 | A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 380 | MedImmune LLCINDUSTRY | 9 | Mar 6, 2020 | clinicaltrials |
| NCT03106428 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | completed | Phase 1 | 67 | MedImmune LLCINDUSTRY | 3 | Feb 28, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | terminated | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 24, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03425773 | Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care(BVAC-B) | completed | Phase 1 | 8 | Cellid Co., Ltd.INDUSTRY | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02608034 | A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | completed | Phase 1 | 32 | Genentech, Inc.INDUSTRY | 4 | Feb 12, 2020 | clinicaltrials |
| NCT02219724 | A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 174 | Genentech, Inc.INDUSTRY | 6 | Feb 5, 2020 | clinicaltrials |
| NCT00446290 | Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer | completed | Phase 1 | 22 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00565370 | Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP | completed | Phase 1 / Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01045538 | Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP | completed | Phase 1 / Phase 2 | 45 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01049620 | RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX | completed | Phase 1 | 40 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03086291 | A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy | unknown | Phase 1 | 9 | Samsung Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT01988896 | Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 153 | Hoffmann-La RocheINDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT02000947 | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer(D4190C00006) | completed | Phase 1 | 459 | MedImmune LLCINDUSTRY | 9 | Oct 31, 2019 | clinicaltrials |
| NCT02471846 | A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 158 | Genentech, Inc.INDUSTRY | 4 | Oct 22, 2019 | clinicaltrials |
| NCT01004224 | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 14 | Oct 4, 2019 | clinicaltrials |
| NCT02773459 | MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 31 | Seoul National University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials